tiprankstipranks
Trending News
More News >
SAB Biotherapeutics (SABS)
NASDAQ:SABS
US Market

SAB Biotherapeutics (SABS) Ratios

Compare
308 Followers

SAB Biotherapeutics Ratios

SABS's free cash flow for Q3 2025 was $0.00. For the 2025 fiscal year, SABS's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 24Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
10.50 2.98 5.45 1.47 1.90
Quick Ratio
10.50 2.98 5.45 1.47 1.90
Cash Ratio
2.73 1.12 5.23 1.00 1.26
Solvency Ratio
-0.99 -1.61 -1.44 -0.78 -0.36
Operating Cash Flow Ratio
-3.45 -4.30 -2.32 -1.56 0.08
Short-Term Operating Cash Flow Coverage
-37.71 -42.24 -23.90 -30.36 1.11
Net Current Asset Value
$ 94.90M$ 5.57M$ 32.27M$ 2.25M$ 7.60M
Leverage Ratios
Debt-to-Assets Ratio
0.03 0.11 0.07 0.12 0.10
Debt-to-Equity Ratio
0.04 0.18 0.10 0.19 0.22
Debt-to-Capital Ratio
0.04 0.15 0.09 0.16 0.18
Long-Term Debt-to-Capital Ratio
0.03 0.00 0.00 0.02 0.00
Financial Leverage Ratio
1.11 1.70 1.46 1.64 2.10
Debt Service Coverage Ratio
17.91 -25.65 -27.91 -14.10 -7.27
Interest Coverage Ratio
-174.11 -134.77 -120.76 -95.89 -45.48
Debt to Market Cap
0.16 0.02 0.03 0.05 <0.01
Interest Debt Per Share
0.60 0.54 1.13 1.43 2.03
Net Debt to EBITDA
-1.05 0.15 1.33 0.60 1.62
Profitability Margins
Gross Profit Margin
-2647.64%-262.41%-67.26%86.23%97.28%
EBIT Margin
16554.61%-2554.95%-1870.43%-77.03%-27.68%
EBITDA Margin
19302.25%-2192.54%-1703.13%-63.26%-24.96%
Operating Profit Margin
-37657.13%-3244.87%-1700.54%-120.98%-22.00%
Pretax Profit Margin
16338.32%-2579.03%-1884.50%-78.29%-28.16%
Net Profit Margin
-18629.86%-2579.03%-1884.50%-78.40%-28.16%
Continuous Operations Profit Margin
16338.32%-2579.03%-1884.50%-78.40%-28.16%
Net Income Per EBT
-114.03%100.00%100.00%100.14%100.00%
EBT Per EBIT
-43.39%79.48%110.82%64.72%128.01%
Return on Assets (ROA)
-11.65%-77.17%-50.27%-36.82%-21.13%
Return on Equity (ROE)
-38.08%-131.33%-73.64%-60.34%-44.47%
Return on Capital Employed (ROCE)
-25.02%-118.49%-52.07%-80.53%-24.49%
Return on Invested Capital (ROIC)
-24.87%-115.89%-50.78%-77.51%-23.18%
Return on Tangible Assets
-11.65%-77.17%-50.27%-36.82%-21.13%
Earnings Yield
-50.36%-97.16%-111.08%-73.00%-5.05%
Efficiency Ratios
Receivables Turnover
0.20 24.06 0.00 4.30 7.60
Payables Turnover
1.07 2.83 3.96 0.89 0.37
Inventory Turnover
0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
<0.01 0.07 0.09 0.84 1.97
Asset Turnover
<0.01 0.03 0.03 0.47 0.75
Working Capital Turnover Ratio
<0.01 0.04 0.08 1.55 2.58
Cash Conversion Cycle
1.44K -113.90 -92.19 -323.08 -935.86
Days of Sales Outstanding
1.78K 15.17 0.00 84.85 48.03
Days of Inventory Outstanding
0.00 0.00 0.00 0.00 0.00
Days of Payables Outstanding
342.24 129.07 92.19 407.92 983.89
Operating Cycle
1.78K 15.17 0.00 84.85 48.03
Cash Flow Ratios
Operating Cash Flow Per Share
-3.50 -3.70 -4.55 -5.39 0.46
Free Cash Flow Per Share
-3.50 -3.74 -4.59 -5.89 -2.06
CapEx Per Share
<0.01 0.04 0.04 0.50 2.52
Free Cash Flow to Operating Cash Flow
1.00 1.01 1.01 1.09 -4.51
Dividend Paid and CapEx Coverage Ratio
-673.02 -101.68 -127.41 -10.83 0.18
Capital Expenditure Coverage Ratio
-673.02 -101.68 -127.41 -10.83 0.18
Operating Cash Flow Coverage Ratio
-6.02 -7.34 -4.25 -3.96 0.23
Operating Cash Flow to Sales Ratio
-324.94 -25.93 -11.22 -0.98 0.03
Free Cash Flow Yield
-98.12%-98.65%-66.65%-99.82%-2.64%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-1.99 -1.03 -0.90 -1.37 -19.80
Price-to-Sales (P/S) Ratio
331.67 26.54 16.96 1.07 5.58
Price-to-Book (P/B) Ratio
0.26 1.35 0.66 0.83 8.81
Price-to-Free Cash Flow (P/FCF) Ratio
-1.02 -1.01 -1.50 -1.00 -37.90
Price-to-Operating Cash Flow Ratio
-1.14 -1.02 -1.51 -1.09 170.87
Price-to-Earnings Growth (PEG) Ratio
-0.05 0.02 -0.01 -0.15 0.11
Price-to-Fair Value
0.26 1.35 0.66 0.83 8.81
Enterprise Value Multiple
0.67 -1.06 0.33 -1.09 -20.72
Enterprise Value
14.80M 30.87M -12.67M 16.55M 314.81M
EV to EBITDA
0.67 -1.06 0.33 -1.09 -20.72
EV to Sales
129.07 23.35 -5.66 0.69 5.17
EV to Free Cash Flow
-0.40 -0.89 0.50 -0.65 -35.15
EV to Operating Cash Flow
-0.40 -0.90 0.50 -0.71 158.44
Tangible Book Value Per Share
15.48 2.80 10.38 7.14 8.87
Shareholders’ Equity Per Share
15.48 2.80 10.38 7.14 8.87
Tax and Other Ratios
Effective Tax Rate
0.00 0.00 0.00 >-0.01 0.00
Revenue Per Share
0.01 0.14 0.41 5.49 14.00
Net Income Per Share
-2.00 -3.68 -7.64 -4.31 -3.94
Tax Burden
-1.14 1.00 1.00 1.00 1.00
Interest Burden
0.99 1.01 1.01 1.02 1.02
Research & Development to Revenue
272.11 22.81 7.38 1.52 0.94
SG&A to Revenue
23.85 0.00 10.63 0.69 0.28
Stock-Based Compensation to Revenue
10.81 2.22 1.08 0.11 0.04
Income Quality
1.74 1.01 0.60 1.25 -0.12
Currency in USD